Uploaded via media manager.

ARC’s role in the Pfizer COVID-19 vaccine trial for 12-to-15-year-olds

To date, vaccines have not been available to children under 16 years old, except those who joined the Pfizer study last year. The 2,260 adolescents who signed up included patients of Austin Regional Clinic.

"ARC had about 5 percent of that enrollment. So about 100 of those 12-15 year old’s in the study came through ARC, from the community here from Austin," said Dr. Anas Daghestani, CEO of Austin Regional Clinic, in this recent interview on Fox7 News.

“Judging from the response of parents bringing their children in for these COVID-19 trials, there’s a lot of excitement,” said ARC Chief Medical Information Officer and internal medicine physician Dr. Manish Naik in another interview on KXAN News.

For those parents who may still be skeptical, however, Dr. Naik says the data looks promising that the Pfizer vaccine is proving safe for kids. Some parents also point out that even is their kids get COVID, the complications are not as dire. “We hear a lot, and it's true, that children at that age do very well, but I just looked at the Travis County dashboard earlier this week, 2 percent of the hospitalizations were in that age group in children. So yes, they do very, very well, but some still get sick," Dr. Daghestani said.

Dr. Naik says the FDA will still have to study those findings, but he expects that at the least, older children could be offered a vaccine in time for the 2021-22 school year.

Last week, Pfizer began testing their vaccine on children 5 to 11 years old and the company has plans to include children as young as 6 months as trials continue. Results from those studies are expected to be available later this year.

Tags: ARC Clinical Research

More on this Topic

Texas, including Austin, is leading the way in COVID-19 research

Texas has emerged as a leading site for COVID-19 research, both in the search for a vaccine and for treatments for active cases. ARC Clinical research, part of this trend, has been running a COVID-19 vaccine clinical trial since early August.

ARC COVID-19 vaccine trial to continue on schedule

In response to announcements of the possible release of a COVID-19 vaccine as early as October 2020, ARC has said it will continue its vaccine trial. Dr. Anas Daghestani, CEO of ARC has said, “Our timeline is still the same.”

ARC Clinical Research contributes to COVID-19 Vaccine Trial

ARC Clinical Research is excited to announce its participation in a prominent COVID-19 vaccine clinical trial that will begin in early August 2020.  ARC will recruit 250 ARC patients from across Central Texas to enroll in this late phase clinical trial. If you are interested in enrolling, please request to participate at ARCclinicalresearch.com or call 512-225-5931.

ARC Teams with Austin-based ENTvantage Diagnostics Dx for New Clinical Trial

ARC’s newest clinical trial tests a device that could help curb antibiotic overuse, "one of the most urgent threats to the public’s health,” according to the Centers for Disease Control (CDC).

ARC Begins Clinical Trials for First-of-its-Kind Device for Antibiotic Overuse

If you live in Central Texas, commonly referred to as an “allergy capital”, chances are you or a family member have suffered a sinus infection, also known as sinusitis. And chances are, if you have had sinusitis, an antibiotic has been prescribed. Yet, according to public health experts, the vast majority of sinusitis cases are not helped by antibiotics.